Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of the American College of Cardiology
- Publicado em
- 7 nov 2025
- Citações
- 14
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial
Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Janet B McGill, Amy Mottl, Masaomi Nangaku, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Carolina Solis-Herrera et al.
Descritores MeSH
- Sodium-Glucose Transporter 2 Inhibitors
- Benzhydryl Compounds
- Diabetes Mellitus, Type 2
- Glucosides
- Hyperkalemia
- Naphthyridines
- Renal Insufficiency, Chronic
- Drug Therapy, Combination
- Female
- Glomerular Filtration Rate
Veja também
Estudos relacionados
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
- Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
- COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
- Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial